Compare MLEC & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | AKTX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Cayman Islands | United States |
| Employees | N/A | 12 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 11.3M |
| IPO Year | N/A | 2014 |
| Metric | MLEC | AKTX |
|---|---|---|
| Price | $9.41 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | ★ 2.0M | 192.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.42 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.22 |
| 52 Week High | $23.22 | $1.72 |
| Indicator | MLEC | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 50.28 |
| Support Level | $1.52 | $0.25 |
| Resistance Level | $12.96 | $0.27 |
| Average True Range (ATR) | 3.36 | 0.02 |
| MACD | -0.78 | 0.00 |
| Stochastic Oscillator | 9.27 | 50.94 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.